Life Sciences Tools and Services

Codexi

Codexi released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 31.47M, actual EPS USD -0.6264

Codexi released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 8.601 M (forecast USD 18.52 M), actual EPS USD -0.2173 (forecast USD -0.1485)

Codexi to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 18.52 M, EPS USD -0.1485

Codexi released FY2025 Semi-Annual earnings on August 13 After-Market EST, actual revenue USD 22.87 M, actual EPS USD -0.4047

Codexi released FY2025 Q2 earnings on August 13 After-Market (EST), actual revenue USD 15.33 M (forecast USD 14.18 M), actual EPS USD -0.16 (forecast USD -0.1885)

Codexis to Release Q2 2025 Earnings Report

Codexi to Release FY2025 Q2 Earnings on August 13 After-Market EST, Forecast Revenue USD 14.18 M, EPS USD -0.1885

Opaleye Management Inc. Acquires Codexis Inc. Common Stock

Opaleye Management Acquires Codexis Common Stock

Codexis Plans to Attend Jefferies Global Healthcare Conference

Codexi released FY2025 Q1 earnings on May 14 After-Market EST, actual revenue USD 7.543 M (forecast USD 9.663 M), actual EPS USD -0.251 (forecast USD -0.2371)

Codexi to Release FY2025 Q1 Earnings on May 14 After-Market EST, Forecast Revenue USD 9.663 M, EPS USD -0.2371

Codexi released FY2024 annual earnings on February 27 After-Market (EST), actual revenue 59.35 M USD (forecast 65.29 M USD), actual EPS -0.8892 USD (forecast -0.7937 USD)

Codexi released FY2024 Q4 earnings on February 27 After-Market (EST), actual revenue 21.46 M USD (forecast 27.41 M USD), actual EPS -0.1276 USD (forecast -0.0362 USD)

Codexi to Release FY2024 Q4 Earnings on February 27, 2025, After-Market EST; Forecast Revenue 27.41 M USD, EPS -0.0362 USD

abrdn plc Reduces Holdings in Codexis, Inc. by 36.5% in Q4

Codexi released FY2024 9 Months Earnings on October 31 After-Market (EST), with actual revenue of 37.89 M USD and EPS of -0.7745 USD

Codexi released FY2024 Q3 earnings on October 31 After-Market (EST), actual revenue 12.83 MUSD (forecast 11.48 MUSD), actual EPS -0.2865 USD (forecast -0.2387 USD)

Codexi to Release FY2024 Q3 Earnings on October 31 After-Market EST, Forecast Revenue 11.48 M USD, EPS -0.2387 USD

Cantor Fitzgerald Reiterates Buy Rating for Codexis with Target Price of $5.00

Starfighters Space

Aimei Health Tech

T-Rex 2X Long DJT Daily Target ETF

Athira Pharma

Sable Offshore

Zeta Network

Vivakor

Safe and Green Development

Trump Media & Tech

VS MEDIA

Niagen Bioscience

ChromaDex

Agilent Tech

Waters

West Pharmaceutical

WuXi Biologics

Medpace

Repligen

Stevanato Group SpA

Cryoport

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap